Investing In Psychedelics: Why Is It In Such High Demand These Days?
Last reviewed and updated: June 1, 2026.
Key Takeaways
| Legal now | Psilocybin service centers operating in Oregon (2023) and Colorado (2025); ketamine nationwide; MDMA in clinical trials only |
| Biotech stock reality | Most pure-play psychedelic stocks are 80–95% below 2021 peaks; sector has been volatile and speculative |
| MDMA status | FDA declined initial approval in 2024 on data quality grounds; efficacy data remains strong; appeal and new trials underway |
| Biggest market development | Legal psilocybin services in two U.S. states and Australia (TGA approved 2023) represent a real, operating market |
| Investment risk | Clinical-stage psychedelic biotech = venture-level risk; long timelines, binary outcomes, high capital requirements before revenue |
Is investing in psychedelics the next wave in the alternative medicine business? With the cannabis investment boom still ongoing, speculators are keen to catch the next wave of drug legalization. That wave is already taking shape as research institutions and private companies work to make psychedelic therapies available.
Once relegated to the black market, psychedelics now hold promise as clinical treatments for a wide range of ailments. Drugs such as magic mushrooms, LSD, and MDMA have shown great promise in addressing serious mental health issues.
The low toxicity and negligible side effects of many of these treatments have added to the appeal. Public approval of psychedelic research is high, and legislation has paved the way for further studies. This could lead to an accelerated path to market.
RELATED: Legal Psychedelics: The U.S. Cities Where Psilocybin, LSD And Others Are Decriminalized
Changes In Legal Status
Since 1970, psilocybin and LSD have been Schedule I drugs in the United States. Other psychedelic substances, such as MDMA, are also of the Schedule I variety. These drugs remain Schedule I at the federal level, but a number of local initiatives have moved the needle toward legality.
Perhaps, most notably, in 2020 Oregon voted to decriminalize possession of psilocybin mushrooms and to legalize their therapeutic use. Washington, D.C., also voted to decriminalize them that year along with other psychedelic plants. California and New Jersey appear to be on the verge of doing the same. Cities including Denver, Oakland, and Santa Cruz have instituted local decriminalization measures as well.
More substantive policy shifts on the federal level could be on the horizon. Ketamine has already seen major inroads for off-label use. In 2019, Johnson & Johnson’s esketamine nasal spray Spravato got approval as a medication for treatment-resistant depression.
RELATED: What Will Psychedelics Look Like In The Future?
A Legal Shift Is Already Happening
Health Canada, the Canadian agency responsible for oversight of healthcare policy, granted exemptions to four terminally ill patients in 2020. These people were then given psilocybin mushrooms as part of end-of-life care. Further, 16 healthcare professionals were also given exemptions, allowing them to consume psilocybin mushrooms. The agency reasoned that experimentation might allow these clinicians to devise ways for the drug to be used therapeutically.
Canada saw its first legal import of psilocybin mushrooms in 2020. It came from Mydecine, which plans on selling its product to other licensed institutions. The company will also use them in their own PTSD treatment trials. One Canadian business owner is already selling microdoses of psilocybin, despite its illegal status. He has yet to see any legal consequences, which could be a sign that a shift in perception is occurring.
A handful of countries already allow legal possession of psychedelics, and the precedents set there will likely influence policy elsewhere. For example, the Netherlands allows legal possession of the mycelium (or “truffle”) of the psilocybin mushroom. The country plans on using this component in a therapeutic context.
RELATED: What Does An MDMA Hangover Feel Like?
Successful Trials And Regulatory Approval
Yes, broader legal status of psychedelics remains in flux. However, a number of institutions and private companies have gained government approval for research into their beneficial application. This should only add more intrigue about investing in psychedelics.
In 2017, the U.S. FDA granted breakthrough status to an MDMA therapy protocol for PTSD developed by the Multidisciplinary Association for Psychedelic Studies. The next year, status to a program aiming at addressing treatment-resistant depression using psilocybin began development from Compass Pathways. And, in 2019, a program using psilocybin to treat major depressive disorder got approval. These trials are in later stages, meaning they’re likely to produce available drugs in the next several years.
The legitimacy of these trials has been bolstered by the opening of major psychedelic research centers at noted institutions. Both Johns Hopkins University in the U.S. and Imperial College London in the U.K. opened psychedelic research centers in 2019.
The Mental Health Problem
Nearly an eighth of the world’s population will face some sort of mental health challenge in their lifetimes. According to WHO, 264 million people around the globe suffer from depression alone. And a substantial fraction of that population does not respond to conventional treatment approaches.
If existing trials successfully demonstrate the efficacy of psychedelic modes of treatment, investing in psychedelics could become a major untapped market. It’s something many in the investment sector are keeping a close eye on.
RELATED: What Are Psychedelics? We Explain The Differences From Other Drugs
The Appetite For Investing In Psychedelics
Starting in early 2020, a number of companies began offering public options in Canada due to looser regulations. Psychedelics that are Schedule I in the U.S. are Schedule III in Canada. Some 25 psychedelics companies now trade on the Canadian Stock Exchange, and others trade on smaller exchanges.
In September 2020, Compass Pathways became the first psychedelics company to be listed on a major U.S. exchange (NASDAQ). The company is backed by Paypal founder Peter Thiel. Its highly successful IPO paved the way for further offerings.
Though the psychedelics boom bears some similarities to the cannabis explosion of the past decade, observers point to notable differences. Since psychedelic drugs are Schedule I in the U.S., the development process is much slower. Institutions wishing to work with the psychedelic drugs must deal with extensive licensing procedures. This substantially extends the development period and creates additional costs.
So Is Investing In Psychedelics Right Now A Smart Move?
Even if the initial trials are successful, the path to FDA acceptance is also long and far from a certainty. Furthermore, a patent isn’t available for specific psychedelic drugs. This creates a very competitive market for derivatives, novel molecules, or proprietary formulations. This only makes the outlook for investing in psychedelics blurrier.
It is also worth noting that, unlike existing psychiatric drugs, some psychedelics treatment requires minimal doses to be effective. This leaves questions about sustainable production of these drugs long-term. Companies such as MindMed are thus pursuing diverse options based on an array of psychedelics.
While investing in psychedelics currently appeals to those with a high risk appetite, growth could reach $6.85 billion by 2027. Eventually, it could be worth over $100 billion. Even a small investment now in the right company could pay major dividends in the next several decades.
RELATED READING
- What Is Psychedelic Therapy? Here’s What The Research Says
- Psychedelics Show Promise For A Range Of Mental Health Conditions
- Is Ketamine Therapy Safe?
Where The Investment Thesis Stands: What Has Actually Happened Since 2021
This article was written in 2020–2021, when psychedelic biotech was in a speculative early phase and the “$6.85 billion by 2027” projection was the common industry cite. The five years since have provided a far more complicated picture — one that matters to anyone still considering psychedelics as an investment thesis.
The Biotech Sector Was Brutally Punished
Compass Pathways went public on NASDAQ in September 2020 at $17/share; it peaked above $60 in 2021 before falling sharply — trading in the single digits for most of 2023–2025. ATAI Life Sciences (NASDAQ: ATAI) and MindMed (NASDAQ: MNMD) followed similar trajectories: massive post-IPO enthusiasm, then steep corrections as trials proved expensive and timelines stretched. Most pure-play psychedelic biotech companies have seen 80–95% declines from their 2021 peaks. Retail investors who bought the 2021 hype largely absorbed significant losses.
The MDMA FDA Rejection Changed the Near-Term Narrative
The FDA’s August 2024 rejection of MDMA-assisted therapy for PTSD — developed by Lykos Therapeutics (formerly MAPS PBC) — was the single biggest negative catalyst for the sector. Despite Phase 3 data showing 67% of participants no longer met PTSD diagnostic criteria (vs. 32% for placebo), the FDA declined approval citing data quality and blinding methodology concerns. The appeal is ongoing, but the rejection signaled that even strong efficacy data does not guarantee a clear regulatory path.
Where the Real Opportunity Actually Emerged
The genuine market development since 2021 has occurred in legal services, not biotech stocks. Oregon launched the first licensed psilocybin service centers in the United States in 2023. Colorado followed with facilitator programs beginning in 2025. Australia’s Therapeutic Goods Administration approved psilocybin for treatment-resistant depression in 2023, creating the first formal national medicine approval. These programs represent a real, operating market — though it remains small, premium-priced, and primarily out-of-pocket. Ketamine therapy has expanded dramatically, with over 1,800 verified clinics now operating across the United States and FDA-approved esketamine (Spravato) now covered by many insurance plans for treatment-resistant depression.
The Honest Current Outlook
Institutional investment has largely shifted from public biotech equities toward private clinical research funding, facilities infrastructure, and facilitator training programs. If MDMA or psilocybin ultimately gains FDA approval — and most researchers believe approval will come, though the timeline is unclear — the sector’s long-term trajectory remains significant. The $100 billion projection still circulates, but analysts who remained bullish after the 2021 crash would note that most of that value hasn’t materialized yet, and the path is more complex than the early hype suggested.
Frequently Asked Questions
Can you invest in psychedelic companies right now?
Yes — several psychedelic biotech companies trade publicly on U.S. and Canadian exchanges. Compass Pathways (NASDAQ: CMPS), MindMed (NASDAQ: MNMD), and ATAI Life Sciences (NASDAQ: ATAI) are the most notable. However, the sector has experienced severe volatility since the 2021 peak, with most pure-play psychedelic stocks down 80–95% from their highs. These are highly speculative, long-timeline investments appropriate only for investors who understand clinical-stage biotech risk.
Did the FDA rejection of MDMA kill psychedelic investing?
It significantly damaged near-term sentiment, but it did not end the investment thesis. The rejection was based on data quality concerns from the specific sponsor (Lykos Therapeutics), not on a determination that MDMA is ineffective for PTSD. The efficacy data — 67% remission vs. 32% for placebo — remains some of the strongest in psychiatric clinical trial history. Most sector analysts believe a second submission or new trial will eventually succeed. The bigger question is timeline: if approval takes another 3–5 years, carrying positions through that period requires conviction and patience.
Is ketamine part of the psychedelic investment sector?
Ketamine is the most commercially mature part of the space and also the least speculative. Esketamine (Spravato) is FDA-approved, and IV ketamine clinics operate legally nationwide. The investment opportunity here is in clinic operations and infrastructure rather than drug development — a completely different risk profile from pre-approval biotech. Ketamine therapy is one of the few areas of psychedelic medicine with established, recurring revenue today.
What is the most realistic near-term psychedelic investment opportunity?
Facilitator training programs, service center infrastructure in Oregon and Colorado, and clinical research funding are where most sophisticated investors have focused since the 2021 biotech correction. The legal psilocybin service market is small but real and growing. For public equity investors, Compass Pathways remains the most prominent bet on psilocybin drug development — it is pursuing both therapy protocols and proprietary formulations. Any investment in clinical-stage psychedelic companies should be considered venture-level risk: binary outcomes, long timelines, and high capital requirements before any revenue.
